San Francisco, CA, United States of America

Edward HyungSuk Ha


 

Average Co-Inventor Count = 4.0

ph-index = 5

Forward Citations = 141(Granted Patents)


Location History:

  • San Francisco, CA (US) (2006 - 2014)
  • Great Neck, NY (US) (2016)

Company Filing History:


Years Active: 2006-2016

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Edward HyungSuk Ha: Innovator in Antibody-Drug Conjugates

Introduction

Edward HyungSuk Ha is a prominent inventor based in San Francisco, CA. He has made significant contributions to the field of biotechnology, particularly in the development of antibody-drug conjugates. With a total of 5 patents, his work focuses on innovative solutions for cancer treatment.

Latest Patents

One of Edward's latest patents involves nemorubicin metabolite and analog reagents, as well as antibody-drug conjugates. The invention relates to antibody-drug conjugate compounds of the formula I: Ab-(L-D) where one or more nemorubicin metabolite or analog drug moieties (D) are covalently attached by a linker (L) to an antibody (Ab) that binds to tumor-associated antigens or cell-surface receptors. These compounds hold promise for use in methods of diagnosis or treatment of cancer and other diseases and disorders.

Career Highlights

Throughout his career, Edward has worked with notable companies such as Genentech, Inc. and Cytokinetics, Inc. His experience in these organizations has allowed him to refine his expertise in drug development and innovation.

Collaborations

Edward has collaborated with several talented individuals in his field, including Gustave Bergnes and Panos Kalaritis. These partnerships have contributed to the advancement of his research and the successful development of his inventions.

Conclusion

Edward HyungSuk Ha is a key figure in the biotechnology sector, with a focus on antibody-drug conjugates that have the potential to revolutionize cancer treatment. His innovative work continues to impact the field positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…